Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma Holdings (NASDAQ:ASBP), a developer of patent-pending drug delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. CEO Kraig Higginson will deliver a presentation on May 21, 2025, at 2:30 PM Eastern. The company will also host one-on-one meetings with investors on May 21-22, 2025.
Interested participants can access the virtual presentation through Sidoti's registration link, and a replay will be available on Aspire's investor relations website. This conference provides an opportunity for investors to learn more about Aspire's multi-faceted drug delivery technology and engage directly with management.
Aspire Biopharma Holdings (NASDAQ:ASBP), sviluppatore di una tecnologia di somministrazione di farmaci in attesa di brevetto, ha annunciato la sua partecipazione al prossimo Sidoti Virtual Investor Conference. Il CEO Kraig Higginson terrà una presentazione il 21 maggio 2025 alle 14:30 ora Eastern. L'azienda organizzerà inoltre incontri individuali con gli investitori il 21 e 22 maggio 2025.
I partecipanti interessati potranno accedere alla presentazione virtuale tramite il link di registrazione di Sidoti, e una replica sarà disponibile sul sito delle relazioni con gli investitori di Aspire. Questa conferenza rappresenta un'opportunità per gli investitori di approfondire la tecnologia di somministrazione di farmaci multifunzionale di Aspire e di interagire direttamente con il management.
Aspire Biopharma Holdings (NASDAQ:ASBP), desarrollador de una tecnología de administración de medicamentos en trámite de patente, ha anunciado su participación en la próxima Sidoti Virtual Investor Conference. El CEO Kraig Higginson ofrecerá una presentación el 21 de mayo de 2025 a las 2:30 PM hora del Este. La compañía también llevará a cabo reuniones individuales con inversores los días 21 y 22 de mayo de 2025.
Los interesados podrán acceder a la presentación virtual a través del enlace de registro de Sidoti, y una repetición estará disponible en el sitio web de relaciones con inversores de Aspire. Esta conferencia brinda una oportunidad para que los inversores conozcan más sobre la tecnología multifacética de administración de medicamentos de Aspire y puedan interactuar directamente con la gerencia.
Aspire Biopharma Holdings (NASDAQ:ASBP)는 특허 출원 중인 약물 전달 기술 개발업체로, 다가오는 Sidoti 가상 투자자 컨퍼런스에 참가할 것이라고 발표했습니다. CEO Kraig Higginson은 2025년 5월 21일 오후 2시 30분(동부시간)에 발표를 진행할 예정입니다. 회사는 또한 2025년 5월 21일부터 22일까지 투자자들과 일대일 미팅을 개최합니다.
참여를 원하는 분들은 Sidoti 등록 링크를 통해 가상 발표에 접속할 수 있으며, 발표 녹화본은 Aspire 투자자 관계 웹사이트에서 제공될 예정입니다. 이번 컨퍼런스는 투자자들이 Aspire의 다면적 약물 전달 기술에 대해 더 깊이 이해하고 경영진과 직접 소통할 수 있는 기회를 제공합니다.
Aspire Biopharma Holdings (NASDAQ:ASBP), développeur d'une technologie de délivrance de médicaments en instance de brevet, a annoncé sa participation à la prochaine Sidoti Virtual Investor Conference. Le PDG Kraig Higginson présentera le 21 mai 2025 à 14h30, heure de l'Est. L'entreprise organisera également des réunions individuelles avec des investisseurs les 21 et 22 mai 2025.
Les participants intéressés pourront accéder à la présentation virtuelle via le lien d'inscription de Sidoti, et une rediffusion sera disponible sur le site des relations investisseurs d'Aspire. Cette conférence offre aux investisseurs une occasion d'en apprendre davantage sur la technologie multifacette de délivrance de médicaments d'Aspire et d'échanger directement avec la direction.
Aspire Biopharma Holdings (NASDAQ:ASBP), ein Entwickler einer zum Patent angemeldeten Arzneimittelabgabetechnologie, hat seine Teilnahme an der bevorstehenden Sidoti Virtual Investor Conference angekündigt. CEO Kraig Higginson wird am 21. Mai 2025 um 14:30 Uhr Eastern Time eine Präsentation halten. Das Unternehmen wird zudem am 21. und 22. Mai 2025 Einzelgespräche mit Investoren führen.
Interessierte Teilnehmer können über den Registrierungslink von Sidoti auf die virtuelle Präsentation zugreifen, und eine Aufzeichnung wird auf der Investor-Relations-Webseite von Aspire verfügbar sein. Diese Konferenz bietet Investoren die Möglichkeit, mehr über Aspires vielseitige Arzneimittelabgabetechnologie zu erfahren und direkt mit dem Management in Kontakt zu treten.
- None.
- None.
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ
One-on-One Meetings
Inspire will also host virtual one-on-ones with investors on Wednesday, May 21 and Thursday, May 22, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.
A replay of the presentation will be available on the investor relations section of Inspire's website at https://ir.aspirebiolabs.com/events/
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Aspire Biopharma (ASBP) presenting at the Sidoti Virtual Investor Conference?
Who will be presenting for Aspire Biopharma at the Sidoti Conference?
How can investors access Aspire Biopharma's Sidoti Conference presentation?
What are the dates for one-on-one meetings with Aspire Biopharma management?
